OncoMatch/Clinical Trials/NCT03899155
Pan Tumor Rollover Study
Is NCT03899155 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for cancer.
Treatment: Nivolumab · Ipilimumab · Cabozantinib · Trametinib · Relatlimab · Nivolumab + Relatlimab · Capecitabine · Bevacizumab · Temozolomide · Rucaparib · Daratumumab · Regorafinib · Leucovorin · Fluorouracil · Oxaliplatin · Enzalutamide · Sunitinib · Pemetrexed · Pembrolizumab — Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
Check if I qualifyEligibility summary
For patients with cancer.
This summary was generated by AI from the trial's official eligibility criteria and may contain errors. Always confirm with the study team before contacting a site.
US trial sites
- Local Institution - 0220 · Huntsville, Alabama
- University of Arizona College of Medicine · Tucson, Arizona
- Innovative Clinical Research Institute · Lynwood, California
- Local Institution · San Francisco, California
- Local Institution - 0099 · San Francisco, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03899155 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify